Cytogen to supply liquid biopsy platform to 2 US university cancer centers

Cytogen, a company specializing in liquid biopsy, said it will supply SmartBiopsy Platform, its proprietary liquid biopsy equipment, to two university cancer centers on the U.S. West Coast -- the University of California, Los Angeles (UCLA) and the University of Southern California (USC).

According to the company, UCLA will leverage Cytogen’s platform in its research on personalized healthcare for prostate cancer.

By integrating organoid cell culture technology with Cytogen’s liquid biopsy platform, UCLA aims to overcome the limitations of traditional prostate cancer tissue biopsies.

Current biopsy methods involve extracting six to 12 tissue samples from the prostate, which can be both painful and prone to failure.

In contrast, Cytogen's CTC (circulating tumor cell) separation technology allows for rapid cancer diagnosis through a simple blood draw, enhancing patient quality of life and selecting optimal cancer treatments.

USC will utilize Cytogen’s platform for single-cell RNA sequencing-based research. The center plans to use the platform to compare pre-and post-treatment drug responses in cancer patients, ultimately identifying the most effective chemotherapy agents for individual patients.

"Our technology is being recognized in the U.S. market and validated by specialized researchers and medical professionals," a Cytogen official said. "We will continue to actively market our superior CTC-based technology in the U.S. and Japan, aiming to expand opportunities to supply Cytogen’s platform to more major hospitals, pharmaceutical companies, and biotech firms."